Skip to main content
. Author manuscript; available in PMC: 2021 Oct 18.
Published in final edited form as: Brain Res. 2020 Feb 3;1736:146699. doi: 10.1016/j.brainres.2020.146699

Figure 2: The effect of midazolam on miniature IPSCs (mIPSCs) in CA1 pyramidal neurons.

Figure 2:

(A) Schematic of the experimental protocol. After 5 minutes of baseline recording (gray box) at holding potentials (−60, −30, or +30 mV), either vehicle (DMSO) or drug (midazolam, 1 μM) was washed in for 15 minutes at a holding potential of −60 mV. mIPSCs were subsequently recorded for 5 minutes at the holding potentials in vehicle or drug once steady-state was reached (steady-state, black box).

(B, C, D) Representative traces of GABAAR-mediated mIPSCs from three CA1 pyramidal neurons at holding potentials of −60 mV (B), −30 mV (C), or +30 mV (D) in the presence of vehicle (DMSO, left panel) or midazolam (right panel). A CsCl-based internal solution with a Cl− reversal potential of 0 mV was used for all traces. Top traces: Representative mIPSCs during baseline (gray) and steady-state (black) of vehicle or midazolam. Middle trace: Expanded trace to show 800 ms of recording. Bottom traces: Average baseline (gray), steady-state (black), and overlay of mIPSC recordings.